Genetic and pharmacological regulation of the endocannabinoid CB1 receptor in Duchenne muscular dystrophy

Fabio A. Iannotti¹, Ester Pagano², Ombretta Guardiola³, Simone Adinolfi⁴, Valentina Saccone⁴, Silvia Consalvi⁴, Fabiana Piscitelli¹, Elisabetta Gazzero⁵,⁶, Giuseppe Busetto⁷, Diego Carrella⁸, Raffaele Capasso⁹, Pier Lorenzo Puri⁴,¹⁰, Gabriella Minchiotti³ & Vincenzo Di Marzo¹,¹¹

The endocannabinoid system refers to a widespread signaling system and its alteration is implicated in a growing number of human diseases. However, the potential role of endocannabinoids in skeletal muscle disorders remains unknown. Here we report the role of the endocannabinoid CB1 receptors in Duchenne’s muscular dystrophy. In murine and human models, CB1 transcripts show the highest degree of expression at disease onset, and then decline overtime. Similar changes are observed for PAX7, a key regulator of muscle stem cells. Bioinformatics and biochemical analysis reveal that PAX7 binds and upregulates the CB1 gene in dystrophic more than in healthy muscles. Rimonabant, an antagonist of CB1, promotes human satellite cell differentiation in vitro, increases the number of regenerated myofibers, and prevents locomotor impairment in dystrophic mice. In conclusion, our study uncovers a PAX7–CB1 cross talk potentially exacerbating DMD and highlights the role of CB1 receptors as target for potential therapies.

¹Endocannabinoid Research Group, Institute of Biomolecular Chemistry (ICB), National Research Council (CNR), 80078 Pozzuoli, Italy. ²Department of Pharmacy, University of Naples Federico II, 80131 Naples, Italy. ³Institute of Genetics and Biophysics, National Research Council (CNR), 80131 Naples, Italy. ⁴IRCCS Fondazione Santa Lucia Rome, 00143 Rome, Italy. ⁵Gaslini Children’s Hospital, L.go Gaslini 5, 16147 Genova, Italy. ⁶Muscle Research Unit, Experimental and Clinical Research Center, Charité – Universitätsmedizin and Max Delbrück Center, Berlin 13092, Germany. ⁷Department of Neuroscience Biomedicine and Movement, Section of Physiology and Psychology, University of Verona, 37134 Verona, Italy. ⁸Telethon Institute of Genetics and Medicine (TIGEM), 80078 Pozzuoli, Italy. ⁹Department of Agricultural Sciences, University of Naples Federico II, Portici 80055, Italy. ¹⁰Development, Aging and Regeneration Program, Sanford Burnham Prebys Medical Discovery Institute, 10901 N Torrey Pines Rd, La Jolla, CA 92037, USA. ¹¹Canada Excellence Research Chair, Institut Universitaire de Cardiologie et de Pneumologie de Québec and Institut sur la Nutrition et les Aliments Fonctionnels, Université Laval, Québec, QC G1V OA6, Canada. Correspondence and requests for materials should be addressed to F.A.I. (email: fabio.iannotti@icb.cnr.it) or to V.D.M. (email: vdimarzo@icb.cnr.it)
Duchenne’s muscle dystrophy (DMD) represents the most frequent form of hereditary myopathy. It is caused by mutations in the X-linked gene encoding for the structural protein dystrophin, which plays a critical structural role by being part of the dystrophin–glycoprotein complex that physically connects the cytoskeleton to the surrounding extracellular matrix through the cell membrane. Loss of dystrophin function caused by large intragenic deletions (65% of the cases), intragenic duplications (6–10% of the cases), or point mutations associated to other sequence variations (30–35% of the cases) leads to progressive and irreversible muscle wasting and weakness. Since the dystrophin gene is located on the X chromosome, the disease mostly affects young boys with a frequency of approximately 1:3500–5.

Recent studies demonstrated that dystrophin plays a key role also in satellite cells, the muscle stem cells normally deputed to regenerate injured muscle fibers, where the lack of the functional protein causes asymmetric cell division, altered morphogenesis, and inefficient differentiation6–7. Although in both human and murine DMD skeletal muscles the number of satellite cells is higher than healthy tissue, their regenerative capacity is inevitably compromised along with disease progression7–9.

The endocannabinoid signaling system (ECS) is composed of a group of endogenous molecules including: (a) two endogenous lipid mediators, anandamide (AEA) and 2-arachidonoyl-glycerol (2-AG); (b) enzymes controlling AEA and 2-AG biosynthesis and degradation; and (c) two AEA and 2-AG responsive G protein-coupled receptors known as cannabinoid receptor of type 1 (CB1) and type 2 (CB2)11–13. In mammals, the function of the ECS is to control a large variety of physiological processes at both central and peripheral levels13,14. However, the potential role of the ECS in skeletal muscle disorders remains unknown. Recently, we have shown that the muscle levels of 2-AG are decreased during both myotube formation in vitro from C2C12 myoblasts and mouse muscle development in vivo. We also reported that in murine and primary human myoblasts the stimulation of CB1 by endogenous 2-AG or synthetic agonists such as arachidonoyl-2-chloroethylamide (ACEA), promotes myoblast proliferation while countering myoblast differentiation. Opposite effects were observed with rimonabant (SR141716) or AM251, two CB1 antagonists/inverse agonists15.

The aim of the present study was to explore the regulation and function of the endocannabinoid CB1 receptor in skeletal muscle, as well as isolated myoblasts and satellite cells from dystrophic mdx mice or human DMD patients. We demonstrate the existence of a functional interplay between CB1 and PAX7, a key factor regulating muscle regeneration through satellite cell division, and that antagonism of CB1 prevents the loss of muscle activity in dystrophic mice.

Results

CB1 and PAX7 expression in dystrophic skeletal muscles. In order to define the expression levels of CB1 in dystrophic muscles, we dissected from both control and mdx mice, the animal model more used to study DMD16–18, the quadriceps, diaphragm, soleus, and gastrocnemius muscles. All these tissues were isolated at three different time points: (1) before the onset of the disease (3 weeks of age); (2) at the onset of the disease (5 weeks), and (3) 3 weeks after the onset19.

Our qPCR analysis revealed that in the gastrocnemius and quadriceps (vastus intermedius), CB1 mRNA levels show a bell-shaped profile with the highest degree of expression at disease onset and declining then over time (Fig. 1a, b, upper panel). In control muscles, instead, the mRNA levels of CB1 were always comparable to the levels observed at 3 weeks in mdx mice (Fig. 1a, b, upper panel). Intriguingly, the transcript levels of PAX7, the most known master gene regulating satellite cell activation and self-renewal20,21, showed an expression profile very similar to CB1 (Fig. 1a, b, lower panel). A similar expression profile of CB1 and PAX7 was also found in the diaphragm and soleus muscle (data not included). To gain a mechanistic understanding relative to the upregulated expression of CB1 gene in DMD muscles, and to define the specific muscle cell subpopulation responsible for these changes, we performed RNA-sequencing (RNA-seq) experiments on fluorescence-activated cell sorting (FACS)-sorted satellite, macrophage and fibroadipogenic progenitor (FAP) cells freshly isolated from the hind limb muscles of 8-week-old control and mdx mice. As shown in the heat map in Fig. 1c, this approach revealed that CB1 is expressed in satellite, FAP, and, much less, macrophage cells. The expression of specific markers of these cell subtypes is also shown (Fig. 1c). Most importantly, we demonstrated that the lack of dystrophin was accompanied by a significant increase in the transcript levels of CB1, occurring exclusively in satellite cells but not in FAP or macrophages (Fig. 1c). The graph bar (Fig. 1d) shows the quantification of the results. Instead, CB2 was only weakly expressed in satellite or FAP cells, and abundantly present in macrophages, where its expression was significantly increased in mdx mice (Supplementary Figure 1).

To clarify whether the increased expression of CB1 observed in dystrophic muscles was due to increased mRNA expression per cell or instead depended on the increased number of PAX7+ cells, we isolated satellite cells from the gastrocnemius of control and mdx mice during (5 weeks) and after (8 weeks) the onset of pathology. Our results, in agreement with previous findings6–8, indicate that the total number of satellite cells isolated from skeletal muscles of mdx mice was significantly higher than in control mice at both time points (Supplementary Figure 2). However, the fold-increase in satellite cell number appeared to account for increased expression of CB1 and PAX7 only at week 8 (approximately twofold increase of cell number), and much less at week 5 (~1.5-fold of cell number), when the latter and, particularly, the former gene appeared to be expressed more-fold (approximately fivefold and twofold) than what could be accounted for by the increase of satellite cells.

CB1 receptor expression profile in human DMD muscles. Since mdx mice exhibit etiological and symptom differences with human DMD17,18,22, we evaluated the expression profile of CB1 and PAX7 genes in leg muscle biopsy specimens from both healthy and DMD human donors. As shown in Fig. 2a, both genes were significantly upregulated in the muscle of 3-year-old boys affected by DMD, when compared to age-matched healthy controls, and lower in 7-year-old compared to 3-year-old DMD boys. Data from healthy 7-year-old patients are not available, since all the collected samples are usually true positives at this age due to the fact that boys affected by DMD usually exhibit the first symptoms around 3–5 years of age23.

2-AG levels in dystrophic murine and human muscles. In both whole muscles and myoblasts of DMD boys (Fig. 2b and Supplementary Table 1) as well as in the muscles of mdx mice (Fig. 2c, d), we found levels of 2-AG in the μM range sufficient to constitutively activate CB1 receptors. No statistically significant differences were observed in 2-AG levels of healthy and DMD donors (Fig. 2b), while higher levels of 2-AG were found in the muscles of 3-week-old mdx mice (Fig. 2c, d). However, 2-AG levels in both mdx mouse quadriceps and gastrocnemius, and in control gastrocnemius, first decreased (from 3 to 5 weeks of age) and then increased (from 5 to 8 weeks of age). Interestingly, 2-AG
levels in the gastrocnemius were higher in mdx mice at 8 weeks than 3 and 5 weeks, when the tissue contained also the highest number of satellite cells (Supplementary Figure 2), in agreement with the hypothesis that these cells are an important source of the endocannabinoid. Satellite cells from control and mdx mouse hind limb muscles expressed similar levels of mRNAs of enzymes for 2-AG biosynthesis and hydrolytic inactivation (Fig. 2e), confirming that these cells contain the enzymatic apparatus to produce and inactivate 2-AG.

**PAX7 directly regulates the transcriptional activity of CB1 gene.** In view of the very similar expression profile of PAX7 and CB1 in both human and murine skeletal muscles affected by DMD, we explored the possibility of a direct regulation of CB1 gene transcription by PAX7. To prove this, we used bioinformatics tools to search for putative consensus sequences for PAX7 within the CB1 gene. The human CB1 gene (CNR1) produces six splice variants. Transcript variants 1, 3, 4, 5, and 6 encode full-length CB1, which is 472 amino acids in length encoded without introns. Transcript variants 1, 3, 4, 5, and 6 encode full-length CB1, while variant 2 that encodes the truncated CB1 is 287 amino acids in length encoded without interruption by a single region in exon 4. Exon 4, however, can be differentially spliced to remove 102 nucleotides (nts). This splicing occurs in transcript variant 2 that encodes the truncated CB1 isoform b. The third isoform, named CB1a (or CB1 short), differs by 167 nts from the isoform b. Furthermore, two transcriptional start sites (TSS) are present at the 5′ end of exon 4. Translation from the former site produces CB1 and CB1b. Translation from the latter site is thought to produce the amino-terminal variant CB1a. On the other hand, the mouse and rat CB1 genes are located on chromosomes 4 and 5, respectively. A single coding variant of CB1 has been identified in these two species. We identified distinct putative PAX7 binding sequences with a high homology score (>90) in both human and murine CB1 encoding genes. In human CB1 gene, we found two PAX7-rich sites located at −560 and −427 bp from the TSS producing the isoforms CB1 and CB1b. Three rich regions were instead found at −427, −390, and −338 from the TSS producing the isoform CB1a or CB1 short. Additionally, a further PAX7-rich region was detected 1175 bp downstream the TSS of CB1a (Fig. 3a). In murine CB1 gene, we found two distinct putative consensus regions for PAX7 located in the 5′UTR region at −232 and −182 bp of distance from TSS (Fig. 3b). Chromatin immunoprecipitation (ChIP) analysis showed that the transcription factor PAX7 effectively binds the putative responsive sequences identified within the CB1 encoding genes. Briefly, in these experiments, the genomic DNA was isolated from gastrocnemius muscles of both control and mdx mice at 5–6 weeks of age and used for the immune-affinity reaction with a specific anti-PAX7 antibody. Subsequently, using specific pair of primers able to amplify the genomic portion of interest of the CB1 gene containing the putative PAX7 binding sites (Fig. 3a, b, red arrows), we found that PAX7 effectively binds these sites and that the amounts of the complex are significantly higher in muscles of dystrophic than healthy mice (Fig. 3c, left). To prove the binding of PAX7 to the human CB1 gene, we repeated the ChIP procedure in primary human PAX7-silenced satellite cells. In these latter experiments, due to the fact that ChIP analysis requires a large number of cells, we were able to study the potential binding of PAX7 to CB1 only within region 2. This portion of the gene was preferred to the other two (regions 1 and 3) because it

**Fig. 1 CB1 and PAX7 gene expression in dystrophic skeletal muscles and cells.** a, b Time course of CB1 and PAX7 mRNA expression levels in gastrocnemius (a) and quadriceps (b) muscle of control (dark yellow columns) and mdx (red columns) mice of 3 (n = 8), 5 (n = 8), and 8 (n = 8) weeks of age. The quantification of transcripts for CB1 and PAX7 was performed by quantitative real-time PCR. c Heatmap representation of selected genes obtained from RNA-seq analysis in fibroadipogenic (FAP), satellite (SC), and macrophage (MP) cells isolated from 8-week-old control (n = 4) and mdx (n = 4) mice. Red, upregulated; green, downregulated. d Bar graph showing RPKM (Reads Per Kilobase of transcript per Million mapped reads) normalized values for the CB1 gene expression level at 5′UTR region at −232 and −182 bp of distance from TSS (Fig. 2c). Chromatin immunoprecipitation (ChIP) analysis showed that the transcription factor PAX7 effectively binds the putative responsive sequences identified within the CB1 encoding genes. Briefly, in these experiments, the genomic DNA was isolated from gastrocnemius muscles of both control and mdx mice at 5–6 weeks of age and used for the immune-affinity reaction with a specific anti-PAX7 antibody. Subsequently, using specific pair of primers able to amplify the genomic portion of interest of the CB1 gene containing the putative PAX7 binding sites (Fig. 3a, b, red arrows), we found that PAX7 effectively binds these sites and that the amounts of the complex are significantly higher in muscles of dystrophic than healthy mice (Fig. 3c, left). To prove the binding of PAX7 to the human CB1 gene, we repeated the ChIP procedure in primary human PAX7-silenced satellite cells. In these latter experiments, due to the fact that ChIP analysis requires a large number of cells, we were able to study the potential binding of PAX7 to CB1 only within region 2. This portion of the gene was preferred to the other two (regions 1 and 3) because it
contains the highest number of putative PAX7 binding sites (Fig. 3a). Furthermore, we transfected human satellite cells with siRNA sequences against PAX7 and collected them after 48 h to perform ChIP analysis. As shown in the right panel of Fig. 3c (right), we found in PAX7-silenced primary satellite cells a ~50% reduction of the intensity of the signal corresponding to the binding of PAX7 to CB1.

To test the efficacy of the siRNA sequences used to target PAX7, we performed qPCR and western blot analyses, which confirmed not only the knockdown of the transcription factor but also that of its major target LIX126, and of the CB1 (but not CB2) gene (Supplementary Figure 3).

Finally, we utilized human embryonic kidney (HEK293) cells to overcome the problems due to the difficulty of isolating a sufficient number of human satellite cells to perform functional luciferase assays. When HEK293 cells were transiently transfected with human PAX7 or control plasmid (scramble), our ChIP analysis confirmed that PAX7 binds with high affinity the endogenous CB1 gene within regions 2 and 3 (Fig. 3d). We then confirmed that PAX7 binding to CB1 enhances its transcription by performing luciferase assays following the cloning of the portion of either the human or murine CB1 gene containing the PAX7 consensus regions in a PGL3 plasmid, upstream of the luciferase gene. In particular, we cloned: a) two human CB1 genomic portions of interest including the two distinct PAX7 consensus regions identified at 5’UTR and downstream the TSS region of CB1a (370 and 319 bp, black bars Fig. 3a, b) the murine CB1 portion of interest, including the two sites identified in the 5’UTR region (703 bp, black bar Fig. 3b). The three constructs were separately transfected into HEK293 cells with or without a plasmid expressing PAX7, which expressed the protein at detectable levels in a variety of non-muscle cell lines. As shown in Fig. 4, when HEK293 cells were transfected with the plasmid carrying the murine or human CB1 genomic portion of interest in the presence of PAX7, the chemiluminescent signal intensity was significantly higher (by about threefold and 6.5-fold, respectively) than when PAX7 was not co-expressed.

Taken together, these results indicate that the transcriptional factor PAX7 directly regulates CB1 gene expression by promoting its transcriptional activity in both murine and human species, showing more efficacy during DMD progression.

**Pharmacological role of CB1 in human muscle cells.** Using western blot analysis, we found that the CB1 protein is expressed in PAX7-positive primary human satellite cells (Fig. 5a). Then, when these cells were induced to differentiate into myotubes, we found that blockade of CB1 receptor by rimonabant (1–3 µM) increased the expression of troponin-T-1 (TNNT1), myogenin (MYOG), and myosin heavy chain (MyHC), canonical markers of myogenesis27 (Fig. 5b, c), while it reduced the proliferation rate of satellite cells (Supplementary Figure 4). The stimulation of CB1 by 2-AG or ACEA (3 µM) produced the opposite effects (Supplementary Figure 4).

To test a potential endocannabinoid-based therapeutic treatment for DMD patients, and given the remarkable difficulty in isolating satellite cells from a muscle biopsy specimens28, we isolated primary myoblasts from nine different donors (ranging from 1 to 7 years old) diagnosed with DMD caused by different mutations in the dystrophin gene (Supplementary Table 2). Proliferating myoblasts at a confluency of about 80–90% were...
exposed to the differentiation media plus vehicle (dimethyl sulfoxide (DMSO)) or rimonabant (1 µM) for 5 days. At the end of treatment, the expression of MYOG and TNNT-1 was quantified by qPCR analysis. We found that rimonabant increased the expression of TNNT-1 and MYOG in differentiating myoblasts isolated from patients D1 to D6, whereas in patients D7-D8 and in patient D9 there was a partial or no effect, respectively (Fig. 5d). However, when combining the results of myoblasts from all patients, we observed a significant difference in the expression levels of MYOG and TNNT-1 between vehicle- and rimonabant-treated myoblasts (Fig. 5e).

**Effect of CB1 antagonism on locomotor activity in mdx mice.**

We next treated mdx mice with ACEA or rimonabant and measured their muscle coordination and strength by the use of rotarod and weight holding tests. These are currently the most commonly used tests to evaluate muscle skills in dystrophic mice.29,30 At the week of disease onset (5 weeks), dystrophic mice were randomized into three groups, receiving vehicle (DMSO, control), 0.5 mg Kg\(^{-1}\) rimonabant, or 2.5 mg Kg\(^{-1}\) ACEA. Each drug was injected intraperitoneally three times per week. As shown in Fig. 6a, at 5 weeks, the locomotor activity of mdx mice, when compared to control animals, was significantly reduced, and then further worsened at 7 weeks (Fig. 6a). At 7 weeks, mdx mice treated with rimonabant, but not ACEA, for 2 weeks showed a significant recovery of their muscle coordination (Fig. 6a). In order to gain information about the effect of rimonabant in a more advanced stage of disease, we repeated the rotarod test at 12 and 18 weeks in the same group of mice chronically treated with rimonabant every other day starting from week 5 (Fig. 6a, the treatment is indicated as chronic). In addition, we also looked at control and mdx mice at an even later stage following rimonabant treatment given every other day starting from week 16 until week 18 (Fig. 6a, the treatment is indicated as 18 short). In either case, rimonabant still prevented the loss of motor coordination. In the weight test, mdx mice were held by the middle/base of their tail to allow them to grasp the weight (from 20 to 60 g). From the moment the mouse grasps the weight with its forepaws, the interval of time during which the mouse can hold the weight is recorded and a score is assigned.30 Also in this case, we found that, as compared to control, in mdx mice muscle strength was significantly impaired at 5 weeks of age, and that, at 7 weeks, rimonabant, but not ACEA, significantly rescued the loss of strength (Fig. 6b). The rescue was also observed at 12 and 18 weeks following both treatment regimens with rimonabant (Fig. 6b). Finally, the above therapeutic effects of rimonabant were confirmed also with a 2-week late treatment in aged mice, from 32 to 34 weeks (Fig. 6a, b).

**Effect of CB1 antagonism on muscle regeneration in mdx mice.**

We next isolated skeletal muscles from mdx mice at the end of treatment to perform histological analyses following sectioning and staining with hematoxylin and eosin (H&E), which is commonly used to evaluate changes in the number of healthy or

---

**Fig. 3** Bioinformatics and ChIP analysis. Schematic representation of the human (a) or murine (b) CB1 gene. The transcriptional start site (TSS) for each gene isoform is indicated. The identified PAX7 sites are shown as small black rectangles below the schematic. Regions identified as 1-4, indicated by red arrows, correspond to PAX7-containing gene regions of high sequence homology in human and murine CB1 gene. c PAX7 occupancy of identified sites in the CB1 gene evaluated by chromatin immunoprecipitation (ChIP) analysis. Left: average data of the relative amount of the PAX7-immunoprecipitated DNA in the murine quadriceps muscle isolated from either wild-type or mdx mice; Right: average data of the relative amount of the PAX7-immunoprecipitated DNA in PAX7-silenced satellite cells. Data are from six separate experiments and normalized relative to the input DNA. The inset shows a representative agarose gel electrophoresis of the qPCR products obtained from PAX7-immunoprecipitated DNA for each experimental condition. d Left: representative agarose gel electrophoresis of the qPCR products obtained from PAX7-immunoprecipitated DNA for each experimental condition. Right: average data of the relative amount of the PAX7-immunoprecipitated DNA in HEK293 cells transfected with control scramble (n = 4) human PAX7 construct (n = 4). \(P \leq 0.05\) vs. control group, determined by Student’s t-test.
necrotic myofibers, position of nuclei within each myofiber, tissue infiltration of inflammatory or fat cells, fibrosis, etc.\textsuperscript{31}. The H&E staining revealed that in the gastrocnemius of 7-week-old dystrophic mice, there was a significant degeneration of skeletal muscle structures as compared to control animals of the same age, as shown in representative images (Fig. 7a). This was characterized by a robust reduction in the number of myofibers or of their diameter with centrally positioned nuclei (Fig. 7a). Treatment with rimonabant prevented these features (Fig. 7a) and significantly increased the number of regenerated myofibers, which exhibited larger size than both wild type and control group (Fig. 7a). All the effects observed in rimonabant-treated mdx mice were quantified and reported in the graphs (Fig. 7b–e). Somewhat less strong, but still significant, protective effects were found in the quadriceps (vastus intermedius) (Supplementary Figure 5). This different efficacy might be due to the higher proportion of slow twitch fibers in vastus intermedius than in gastrocnemius, where CB1 is more abundantly expressed\textsuperscript{32,33} (Supplementary Figure 5). This could suggest that tonic activation of CB1 in the quadriceps is lower than in the gastrocnemius, also by virtue of the lower levels of 2-AG between 5 and 8 weeks of age (Fig. 2), and hence less efficaciously unmasked by a saturating dose of rimonabant. In addition, we isolated satellite cells from the gastrocnemius of control and dystrophic mice treated with rimonabant or vehicle. We found that, in mdx mice, rimonabant significantly reduced the number of satellite cells as compared to vehicle-treated mice and, at week 5, also to healthy mouse gastrocnemius (Fig. 7e), in agreement with the pro-differentiating effect of the CB1 antagonist observed here also in vivo (see below).

In summary, we show that in vivo, more prominently than in vitro, CB1 antagonism reduces the amount of proliferating satellite cells. In addition, the fact that after treatment with rimonabant the number of proliferating satellite cells was lower than in control mouse muscles, likely indicates that in dystrophic muscles PAX7 positively regulates CB1 to promote its tonic activation by endocannabinoids, which in turn increases the proliferative status of satellite cells.

**Rimonabant reduces the expression of degenerative markers.**

We evaluated the transcript levels of known genes involved in the inflammatory and degenerative process in the muscles of control and mdx mice of 7 weeks treated with rimonabant or vehicle. In the gastrocnemius and quadriceps of dystrophic mice, compared to control littermates, we found a significant decrease in the expression level of MyHC and neoMyHC (Fig. 8a, c, e), and, conversely, an increase of the inflammatory markers, interleukin 6 receptor (IL6R), tumor necrosis factor-α (TNFα), transforming growth factor-β (TGF-β), and inducible nitric oxide synthase (iNOS) (Fig. 8a, d, f). In these muscles, 2-week treatment with rimonabant caused a partial or full recovery in the expression levels of neoMyHC and MyHC (Fig. 8a, c, e), whilst reducing the two transcript levels of IL6R, TNFα, TGF-β, and iNOS (Fig. 8b, d, f). We also measured by ELISA the plasma levels of IL6 and TNFα in control and mdx mice treated with rimonabant from 5 to 18 weeks of age every other day. As expected, plasma levels of both IL6 and TNFα were considerably increased in mdx mice, and rimonabant fully reversed this effect (Fig. 8e, f).

**Intracellular mechanism coupled to CB1 receptor stimulation.**

In our previous study, we demonstrated that the stimulation of CB1 activates a typical G protein-coupled receptor-mediated signaling mechanism, that is, the hydrolysis of 4,5-bisphosphate (PIP2), thereby causing the inhibition of myogenesis-promoting voltage-gated potassium K\textsubscript{v}7.4 channels\textsuperscript{132}. The formation of diacylglycerols (DAGs) and inositol trisphosphate (IP3) is known to occur as consequence of protein Gq-mediated PIP2 hydrolysis. Therefore, in order to characterize also in satellite cells the CB1 signaling cascade, we measured the levels of DAGs following CB1 stimulation with ACEA. We found that exposure of satellite cells to ACEA (3 μM) for 20 min elevated the intracellular levels of two arachidonic acid-containing DAG species. Since these DAGs may also act as biosynthetic precursors of 2-AG\textsuperscript{34}, we also measured the levels of this endocannabinoid, and found them to be significantly increased (Fig. 9a, b). These results raise the possibility that CB1 stimulation may generate a positive loop through increased production and signaling of 2-AG.

In addition, being the members of protein kinase C subfamily (PKCs) preferential targets of DAGs in different cell types\textsuperscript{35,36}, we hypothesized their potential involvement as downstream targets of CB1 receptors. It is known that PKC activation occurs through phosphorylation at distinct sites including Thr-494, Thr-495, and Thr-497\textsuperscript{36}. Therefore, by means of western blot analysis performed using a selective phospho-specific antibody directed against the Thr497 site (common to all PKC isoforms), we analyzed potential changes in PKC phosphorylation in human satellite cells following CB1 stimulation. We found that, in agreement with its stimulation of DAG production, ACEA also increased phosphorylation of PKCs at Thr497, without affecting their expression (Fig. 8c). Notably, in the gastrocnemius of mdx mice at 8 weeks, we found a significant increase in PKC phosphorylation, which might depend on the tonic activation of CB1 by 2-AG, when the levels of this endocannabinoid are highest (Fig. 8d). It is worth noting that PKCs are known to: (a) directly inhibit voltage gated K\textsubscript{v}7 K\textsuperscript{+} channel activity\textsuperscript{37} and (b) exacerbate the inflammatory and immune response in DMD\textsuperscript{38,39}.\n
**Fig. 4** Luciferase assay in PAX7-transfected HEK293 cells. Relative luciferase activity following transfection of human constructs into HEK293 cells. Cells were co-transfected with the pGL3 promoter vector carrying the construct of interest (regions 2, 3, and 4) cloned upstream of the luciferase gene together with an equimolar amount of plasmid encoding for human PAX7. For the control condition, PAX7 plasmid was replaced with pCDNA3.1. Cells were co-transfected with a β-Gal encoding vector to normalize transfection efficiency and the signal intensity of luciferase. The inset on the right shows a representative chemiluminescent signal emitted from the reaction of luciferase from the different experimental conditions. Data are expressed as the mean ± SEM of four independent determinations. *P ≤ 0.05 vs. control group, determined by Student’s t-test.
**Fig. 5** Pharmacological role of CB1 in primary human muscle cells. a Representative blot for CB1 and PAX7 protein expression in primary human satellite cells. The approximate molecular mass for each of these proteins (expressed in kDa) is shown on the right. b Bar graph showing the mRNA expression levels of MYOG and TNNT-1 in satellite cells exposed to DM for 5 days +/− rimonabant 1-3 μM. Each bar is the mean ± SEM of four separate determinations. c Morphological analysis of myotube formation in human primary satellite cells exposed to DM for 5 days. MyHC (red) and DAPI (blue). The fusion index was calculated in both vehicle (DMSO)- and rimonabant-treated cells exposed to DM for 5 days. d Bar graphs showing the MYOG and TNNT-1 mRNA expression levels in primary human myoblasts isolated from DMD donors (D1-D9) and induced to differentiate in presence of vehicle (DMSO) or rimonabant (1 μM). The quantification of transcripts was performed in quadruplicate by quantitative real-time PCR. The error bars correspond to the internal SEM. e The graph shows the differences in the expression levels of MYOG and TNNT-1 between vehicle- or rimonabant-treated myoblasts calculated by combining the DMD patient’s results together. Each bar is the mean ± SEM of the data from the nine patients, each of which was obtained from at least four separate determinations (see d). *P ≤ 0.05 vs. vehicle group, determined by Student’s t test.

**Fig. 6** Effect of rimonabant on locomotor activity of mdx mice treated. The muscle coordination and strength was measured in control (n = 7) and mdx mice treated with vehicle (DMSO, n = 11), ACEA (2.5 mg Kg⁻¹, n = 7), or rimonabant (0.5 mg Kg⁻¹, n = 16 IP every other day) at the beginning of the treatment (5 weeks) and at 7, 12, and 18 (chronic) weeks. The treatment was repeated starting from week 16 until week 18 of age (18 short, control wt = 7; mdx + DMSO = 10; mdx + rimonabant = 10) or from week 32 until week 34 of age (control wt = 7; mdx + DMSO = 10; mdx + rimonabant = 10) by the rotarod (a) and weight (b) tests. Each bar is the mean ± SEM. +P ≤ 0.05 vs. control group, *P ≤ 0.05 vs. mdx vehicle group, determined by Student’s t test.
These results further support the potential use of CB1 antagonists, rather than agonists, to treat DMD.

**Discussion**

Although great advances have been made toward a long-term therapeutic approach to treat DMD, there is still no cure. Complementary and/or supportive therapies are currently used to delay and/or reduce the severity of symptoms. Our previous finding of the crucial role of the endocannabinoid 2-AG and its receptor, CB1, in controlling myoblast proliferation and differentiation in vitro and during early muscle development raised two important questions: (1) is the endocannabinoid system also important for the very first steps in muscle formation, for the generation of myoblasts from satellite cells? (2) Can pharmacological manipulation of CB1 receptors be useful to help treating the symptoms, or delaying the progress, of muscular dystrophies such as DMD? The former question is also relevant to the latter one, since satellite cell dysfunction represents a major feature in muscles affected by DMD. In fact, it was reported that the number of these cells is higher in DMD muscles than in control, regenerated and undamaged muscles of the dystrophic muscles could somehow

**Fig. 7** Effects of rimonabant on muscle degeneration. a Representative photomicrographs of H&E-stained transverse sections of gastrocnemius muscles isolated from wild-type (control, n = 6); mdx mice (without vehicle, n = 6); mdx mice treated with vehicle (DMSO, n = 6), or rimonabant (n = 6) 0.5 mg Kg$^{-1}$ IP from week 5 to week 7 of age. Scale bars = 100 μm. b Total number of myofibers in each section of area (CSA, μm$^2$). c Number of healthy myofibers within each section area (CSA, μm$^2$). d Bar graph indicates the number of necrotic, partially regenerated (recently necrotic), fully regenerated and undamaged myofibers in control (DMSO) and rimonabant-treated mdx mice. Mice were treated from week 5 to week 7 of age. Each bar is the mean ± SEM. *$P \leq 0.05$ vs. vehicle group, determined by Student’s t test. e Bar graph showing the relative number of satellite cells found in the gastrocnemius muscles of control and mdx mice treated with vehicle (DMSO) or rimonabant. Each bar is the mean ± SEM of four independent determinations.

Here we showed that: (1) CB1 is overexpressed in the skeletal muscle and satellite cells of mdx mice, as well as in muscle biopsies of DMD patients, when the first signs of the disease occur, and concomitantly with a peak in expression of PAX7, a key transcription factor and biomarker for satellite cells; (2) CB1 upregulation in satellite cells of mdx mice cannot be accounted for solely by the increased number of these cells in dystrophic muscles, especially at the onset of disease, and hence must be the result of the overactivation of some regulatory pathway; (3) accordingly, PAX7 upregulates the expression of both human and mouse recombinant CB1 in host cells, and binds to the Cnr1 gene in wild type and, to a higher extent, mdx mouse muscle, using specific consensus sequences on this gene; (4) antagonism of CB1 receptors, opposite to their activation, reduces human satellite cell proliferation; in addition, it enhances the formation of myotubes from either satellite cells from healthy tissue, or human myoblasts from DMD patients; and (5) CB1 antagonism in mdx mice, starting at an early age, when their skeletal muscle exhibit the highest expression levels of CB1 and sufficient amounts of 2-AG to activate them, might represent a tool to counteract the loss of muscle strength in dystrophic mice, by enhancing muscle tissue regeneration and possibly reducing inflammation and fibrosis.
Fig. 8 Effect of rimonabant on the expression of inflammation markers. The bar graph shows the expression levels of myosin heavy chain (MyHC) and neonatal-myosin heavy chain (neo-MyHC) (a and c) and/or transforming growth factor β 1 (TGF-β1), tumor necrosis factor α (TNFα), interleukin receptor 6 (IL6R), and inducible nitric oxide synthase (iNOS) (b and d) in the indicated skeletal muscles isolated from control (dark yellow), mdx mice + vehicle (DMSO, red columns) and mdx mice + rimonabant (0.5 mg Kg⁻¹, green columns). Each bar is the mean ± SEM of six separate determinations. e, f Plasma levels of IL6 and TNFα quantified by ELISA in control (n = 4) and mdx mice treated with vehicle (DMSO; n = 4) or rimonabant 0.5 (n = 4) mg Kg⁻¹. *P ≤ 0.05 vs. vehicle group, determined by Student’s t test.

Fig. 9 Measurement DAGs levels and activity in satellite cells and muscles. Levels of diacylglycerols (DAGs) (a) and 2-AG (b), in primary satellite cells exposed to the selective CB1 agonist ACEA 3 µM for 20 min. The levels of 2-AG and DAGs are normalized to the amount of lipids extract (pmol mg⁻¹). Each bar is the mean ± SEM of six separate determinations. *P ≤ 0.05 vs. vehicle group, determined by Student’s t test. c, d Representative blots showing the chemiluminescent signal generated by the anti-phosphospecific (Thr497 site) and non-phosphospecific PKC antibody in satellite cells exposed to ACEA 3 µM for 20 min or d in the gastrocnemius isolated from control (n = 4) and mdx (n = 4) mice at 8 weeks. Quantification of phospho-PKC (pPKC) levels are normalized to total PKC. Each bar is the mean ± S.E.M. of five separate determinations. *P ≤ 0.05 vs. the indicated experimental group, determined by Student’s t test.
participate in the reduced ability of muscle precursor cells to terminate their differentiation into mature myotubes. This hypothesis was confirmed by our findings in: (1) primary human satellite and/or myoblast cells isolated from healthy and DMD patients, where antagonism of CB1 receptor promoted differentiation; and (2) mdx mice, where rimonabant increased significantly the number of healthy/regenerating fibers, and decreased inflammatory markers. It is not possible to assess whether the effect of rimonabant on satellite cell differentiation was due to reduced proliferation or vice versa. Since CB1 activation by ACEA significantly enhanced proliferation but appeared to reduce differentiation to a smaller extent, it is possible that the two processes are not solely the consequence of the other, and, in this case, CB1 antagonists would have the advantage of independently ameliorating two signs of DMD, i.e., satellite cell excessive proliferation and impaired differentiation. Likewise, from our biochemical and histological analyses of mdx mice at the end of treatment, it is not possible to conclude whether the effect of rimonabant on muscle regeneration is the product of reduced inflammation or if the latter effect is a consequence of improved muscle regeneration. Appropriate studies, with time-course analyses of the various effects of rimonabant, need to be performed in order to answer this question, and might demonstrate two independent effects of CB1 antagonism, as suggested by our present data in human DMD myoblasts and previous evidence of the anti-inflammatory properties of rimonabant. Interestingly, the antagonist did not enhance to the same degree the differentiation of myoblasts from DMD patients with different mutations of the dystrophin gene. There is clinical evidence demonstrating that the type of mutated dystrophin does not necessarily correlate with the severity of the disease. Often, in patients with the same mutation disease severity may vary, sometimes even within the same family. Therefore, it is difficult to correlate the different pro-differentiating effects of rimonabant in myoblasts isolated from different patients with the potential clinical or genetic characteristics of the latter. A different pharmacogenomic profile among DMD patients could be one of the main factors determining the response to rimonabant. Future studies on a larger sample of patients are required to fully investigate this hypothesis.

Overactivity of the endocannabinoid system has been described in a large number of disorders including chronic inflammatory conditions involving both central and peripheral systems. For example, in some metabolic dysfunctions caused by excessive inflammation and oxidative stress and characterized by elevated endocannabinoid tone and CB1 expression (i.e., obesity, high fat diet and alcohol-induced liver steatosis/fibrosis, high fat diet-induced β-cell dysfunction, doxorubicin-induced cardiomyopathy, high cholesterol-induced atherogenesis, etc.), CB1 inactivation reduces the infiltration of immune cells, fibrosis, and ROS production in several peripheral organs. Thus, CB1 antagonism as an add-on therapy in DMD might also result in the sparing of steroidal anti-inflammatory drugs, which are responsible for serious side effects in children affected by this disease. Additionally, recent studies (and our unpublished data) on the negative effects of CB1 activation on acetylcholine release from the neuromuscular junction suggest that CB1 antagonists may also effectively ameliorate muscle contraction. However, preliminary data from our laboratory on the lack of rimonabant effect on the isometric contraction of gastrocnemius muscles from 8 weeks old mdx mice, evoked by selective stimulation of the nerve in vivo, suggest that the beneficial effects of CB1 antagonism in the rotarod and weight test, reported here, may not be due to direct amelioration of muscle contraction performance.

In conclusion, we uncovered a potential vicious circle caused by excessive satellite cell proliferation and PAX7 overexpression, subsequent PAX7 binding to CB1, overexpression of this gene and CB1 overactivity, with further satellite cell proliferation and reduction of differentiation. We propose that the endocannabinoid system participates in the development of degenerative muscle disease, through effects on muscle differentiation, regeneration, and repair processes, and suggest that CB1 receptor may represent a potential target for the adjuvant therapy of muscle dystrophies.

Methods

Cell culture, reagents, and transfections. Primary human satellite cells were provided by Innpro (Cat. no. P10976, Biukaia-Spain) or ScienCell (Cat. no. 3510; Ceballos, CA, USA). Satellite cells were propagated in a growth medium (GM) recommended by Innpro (Skeletal Muscle Cell Medium, cat. no. P60124). Myocyte differentiation was achieved after exposure of satellite cells to a skeletal muscle cell differentiation medium (DM) provided by Applied Stem Cell (Cat. no. ASE-5064; CA, USA).

Primary myoblasts were established from the muscle biopsy of DMD affected donors after they had signed informed consent forms and in accordance with the guidelines of the G. Gaslini Institute Ethical Committee. The myoblasts were grown in Full Aneural Medium (Dulbecco’s Modified Eagle Medium (DMEM) High glucose supplemented with 15% FBS, 20% Medium 199, 1% insulin, 1% glutamine, and 1% penicillin and streptomycin, G418, EGF). All the reagents were provided by Life Technologies (Milan, IT).

HEK293 (Human Embryonic Kidney-293; ATCC Number: CRL-11268) cells were propagated in Minimum Essential Media (MEM, cat. no. 31095-029 supplemented with 10% fetal bovine serum (FBS); 50 U/ml penicillin plus 50 µg/ml streptomycin, and 1% glutatione (Invitrogen, Milan, IT), in a humidified atmosphere of 95% air/5% CO2 at 37 °C.

For cell transfection, primary human satellite cells were plated in six multilwell culture dishes; the day after plating, cells were transfected with the esRNA sequences targeting PAX7 (cat. no. EHU023515, Sigma-Aldrich, Milan, IT) using Lipofectamine RNAiMAX (cat. no. 13778-150, ThermoFisher Scientific, Milan, IT) according to the manufacturer’s instructions.

HEK293 cells were seeded onto 24-well plastic plates at a 2 × 104 cells/cm2 density. After plating the cells were transfected on the next day with: (a) pGL3 promoter vector (Promega, IT); cat. no. E176A) with the promoter of interest human gene; (b) human PAX7 GFP-tagged plasmid (Origene, MD USA; cat. no. RG216834); (c) pC3DNA3 (Life Technology, Milan, IT, cat. no. V79020): (d) a plasmid encoding for pSV-β-galactosidase control vector (Promega, IT; cat. no. E1081) was used to normalize the signals and as positive control vector for monitoring transfection efficiency. The combination of plasmids was transfected into the cells by use of Lipofectamine LTX (Life Technology, MI, IT) following the manufacturer’s instructions.

The isolation of satellite cells from mouse skeletal muscle was performed using the gentleMACS TM Dissociator (cat. no. 130-093-235) following the protocol of the skeletal muscle dissociation kit (cat. no. 130-098-305) and the satellite cell isolation kit, mouse (cat. no. 130-104-268). After isolation, cells were counted using an automatic cell counter (Scepter 2.0, Merk Millipore).

Luciferase assay. After 48 h, the cells were harvested to detect the luciferase gene reporter activity by the use of the luciferase assay kit (cat. no. LUCI, Sigma-Aldrich, IT); whereas the β-galactosidase activity was detected with the β-galactosidase detection kit (cat. no. Gal-A, Sigma-Aldrich, Milan, IT). The signal intensity of β-Gal was measured at a microplate readers station (Tecan Geniospro). Whereas, the signal intensity of firefly luciferase was detected on a ChemiDoc MP System station and reported as normalized with respect to the β-Gal.

Bioinformatics and ChIP analysis. Putative PAX7 consensus sequences identification were identified using the match tool of Transfac. The ChIP assay was performed by the use of ChIP Kit (Sigma-Aldrich, Milan, IT; cat. no. CHP1) following the manufacturer’s instructions. The genomic DNA was sonicated, immunoprecipitated overnight at 4 °C with an antibody directed against PAX7 validated for ChIP (anti-PAX7 used at 2 µg/ml; Millipore, clone 2F12H4). Immunoprecipitated DNA was then analyzed by qPCR (40 cycles) using primers amplifying each of PAX7-rich regions identified (Supplemental Table 3). In addition, for each primer pair, non-immunoprecipitated DNA was used as input for normalization. All ChIP assays were performed in triplicate for at least three different biological preparations.

Western blot and immunocytochemistry analysis. Satellite cells were washed twice in cold PBS (without Ca2+ and Mg2+, pH 7.4) and lysed with lysis solution (150 mM NaCl, 1 mM EDTA, pH 7.4, 10 mM Tris-HCL, pH 8, 1% SDS, and 1% protease inhibitors). The same lysis solution was used to extract the protein from whole skeletal muscle tissues. Each animal was previously anesthetized, and once decapitated, the skeletal muscles were quickly dissected and washed twice in cold PBS. After the homogenization cell and/or tissue lysates were kept in orbital
Measurements of endocannabinoids and DAGs. Frozen muscle tissue samples were homogenized in chloroform/methanol/TRIS-HCl 50 mM, pH 7.4 (2:1:1, v/v), containing 5 pmol of [3H]AEA, 50 pmol of [3H]-2-AG, [3H]-PEA, and [3H]-OEA as internal deuterated standards (purchased from Cayman Chemicals, Ann Arbor, MI, USA). The extract was purified by glass gel minicolumn, and the eluted fraction containing endocannabinoids and endocannabinoid-nib molecules analyzed by means of liquid chromatography–atmospheric pressure chemical ionization–mass spectrometry (LC-APCI-MS). LC analysis was performed in the isocratic mode using a Discovery C18 column (15 cm x 4.6 mm, 5 µm) and methanol/water/acetic acid (85:15:1 by vol.) as a mobile phase with a flow rate of 1 ml min⁻¹. Analyses were carried out in the selected ion-monitoring mode using m/z values of 356 and 348 (molecular ions + 1 for deuterated and undeuterated AEA), 384.35, and 379.35 (molecular ions + 1 for deuterated and undeuterated 2-AG). AEA and 2-AG levels were therefore calculated on the basis of their area ratios with the internal deuterated standard signal areas. Lipid amounts expressed as pmol were then normalized per gram or milligram of wet tissue. To measure DAGs, satellite cells were dounce-homogenized and extracted with chloroform/methanol/TRIS–HCl 50 mM (pH 7.5: 1:2:1, v/v), followed by centrifugation for 10 min at 1000×g. The organic phase was dried down, weighed, and pre-purified by open-bed chromatography on silica gel. Fractions were obtained by eluting the column with 99:1, 90:10, and 50:50 (v/v) chloroform/methanol. The 90:10 fraction was used for AEA and 2-AG quantification by LC-APCI-MS by using a Shimadzu high-performance liquid chromatography apparatus (LC-10ADVP) coupled to a Shimadzu high-performance liquid chromatography–atmospheric pressure chemical ionization interface. LC analysis was performed in the isocratic mode using a Discovery C18 column (15 cm x 4.6 mm, 5 µm) and methanol/water/acetic acid (85:15:1 by vol.) as a mobile phase with a flow rate of 1 ml min⁻¹. The amounts of endocannabinoids in plasma, quantified by isotope dilution with the above mentioned deuterated standards, are expressed as pmol ml⁻¹. The volume or milligram of lipid extract weight. The 99:1 fraction was used for DAGs quantification by iodide chromatography–tandem mass spectrometry (LC-MS-MS) using an LC20AB coupled to a hybrid detector IT-TOF (Shimadzu Corporation, Kyoto, Japan) equipped with an ESI interface. DAGs were separated using a Discovery C18 column (2.1 mm x 50 µm, 3 µm) and eluted by an isocratic flow of acetonitrile-2-propanol (85:15). LC20AB HPLC pumps were used to deliver solvent at a flow rate of 200 µl min⁻¹. All molecular and fragment ions were sodiated and hence provide high-resolution values for [M + Na⁺]. We acquired full-scan mS spectra of selected DAG precursor ions by multiple reaction monitoring (MRM) in the chromatographic high-resolution mode n values and used the latter chromatograms for calibration and quantification. DAGs measured included 18:1-20:4 and 18:0-20:4, and the amounts of these species in cells were quantified using the standard, 1,2-heptadecanoin (17:0-17:0), for which a calibration curve had been constructed in pilot experiments for the most abundant DAG species. The other DAG species were expressed as pmols per mg of wet tissue weight. The calibration curve was also run occasionally, with no observed significant changes. All molecular and fragment ions were sodiated and hence provide high-resolution values for [M + Na⁺]. As most 20:4-containing DAG species are present in tissues in trace amounts; in some cases, we could not have the column to be sure to detect these DAG species. We acquired full-scan mS spectra of selected DAG precursor ions by MRM, extracted the chromatograms of the high-resolution [M + Na⁺] values, and used the latter chromatograms for calibration and quantification. The limit of detection (LOD) of 17.0-17.0 was 10 pmol in MS analysis.

Muscle biopsies. All human samples were obtained after the patients had signed informed consent forms in accordance with the guidelines of the Ethics Committee, involved experimental protocols for muscle biopsies. The muscle biopsy was obtained from femoral quadriceps muscle for diagnostic purposes from patients suspected for DMD. The diagnosis of DMD was also confirmed by genetic analysis.

Animals care. The experimental protocol was evaluated and approved by the Institutional Animal Ethics Committee for the use of experimental animals and confirmed to guidelines for the safe use and care of experimental animals in accordance with the Italian D.L. no. 116 of 27 January 1992 and associated guidelines in the European Communities Council (86/609/EEC and 2010/63/UE). For this study, control (C57BL/10ScSn) and dystrophic (C57BL/10ScSn-Dmdmdx/)) mice of 5 weeks weighing ~20–25 g were purchased from Charles River Laboratories (ML, IT). All mice were housed in an individually ventilated cage system with a 12-h light–dark cycle and received standard mouse chow (Harlan Teklad) and water ad libitum.

Drug treatment and reagents. Control (C57BL/10ScSn) or dystrophic (C57BL/10ScSn-Dmdmdx/) mice were intraperitoneally (IP) injected with: (a) vehicle (DMSO); (b) ACEA (2.5 mg Kg⁻¹); or (c) rimonabant (SR141716 0.5 mg Kg⁻¹) three times per week for 2 weeks. DMSO and ACEA were from Sigma Aldrich. Rimonabant was from Cayman Chemical Company (USA).

ELISA assays on plasma of control and dystrophic mice. Control and dystrophic mice treated with vehicle (DMSO) or rimonabant were previously anesthetized with halothane, subsequently the blood was removed by cardiac puncture and collected into EDTA-treated tubes. Blood cells were then removed by centrifugation for 10 min at 1000–2000xg using a refrigerated centrifuge. The resulting supernatant or plasma was further filtered in Amicon Ultra-0.5 ml Centrifugal Filter tubes to concentrate the protein to a molecular weight cut off of ~100 kDa. The ELISA assay was performed by the use of either TNFa (cat. no. KHC3101) or IL-6 (cat. no. KM0061) mouse ELISA Kits purchased from Thermo-Fisher scientific as per the manufacturer’s instruction.

RNA-seq analysis. Hind limb muscles from normal wild-type C57/BL6 and C57Bl6 mdx dystrophic mice, used at the specified age of 8 weeks, were minced and digested in HBSS (Gibco) containing 2 mg ml⁻¹ Collagenase A (Roche), 2.4 U ml⁻¹ Dispase I (Roche), 10 nmol ml⁻¹ DNase I (Roche), 0.4 mM CaCl₂, and 5 mM MgCl₂ for 90 min at 37 °C. Cells were stained with primary antibodies CD31-PB (Biossience), CD45-fluor450 (Bioscience), Ter119-fluor450 (Bioscience), F4/80-eFluo480 (eBioscience), and CD45-eFluor450 (eBioscience) for 30 min on ice. Cells were finally washed and resuspended in 1 ml Fluorescence activation-activated (FACS) solution (BD Pharmingen and 7-aminopropyl-APC (AbLab)) for 30 min on ice. Cells were then washed and resuspended in 1 ml Flow cytometry (BD Pharmingen) and subsequently, for RNA-seq analysis, SCs, FAPs, and MPs freshly isolated by FACS from 16 wild-type C57/BL6 and six C57Bl6 mdx mice, 8-week old, were centrifuged and the pellet was resuspended in Trizol (Invitrogen) for total RNA extraction. About 100 ng µL⁻¹ of total RNA was sent in duplicate to IGA for RNA-seq. RNA for the sequencing was processed using Illumina TruSeq Stranded Total RNA kit RibO-Zero GOLD on Illumina Hiseq2500 platform. Mapping of more than 20 million of reads for each sample to the mouse musculus GRCm38.78 genome was performed using TopHat 2.0.9. Read count was performed with HTSeq-0.6.1p1. Mapped reads were analyzed with R-studio using DESeq2 to obtain normalized RPKM values and Heat-map with Z-score function. Sequencing data are available through SRA accession code SRP143532. For RT-PCR validation, 150 ng of total RNA, isolated from Trizol from SCs, FAPs, and MPs freshly isolated from wild-type C57/BL6 (n = 4) and three C57Bl6 mdx (n = 4) mice 8-week old, was retro-transcribed using the Taqman reverse transcription kit (Applied Biosystems). Real-time quantitative PCR was performed to analyze relative C1, Dagl and Magl gene expression levels using SYBR Green Master mix (Applied Biosystems) following manufacturer indications. The values were normalized to the housekeeping gene TBP for SCs and FAPs and to S16 for MPs.

Rota-rod test. The rotarod test was performed in control and dystrophic mice immediately before the beginning of the pharmacological treatment (5 weeks) and at the indicated times following the treatment with vehicle, ACEA, or rimonabant. Briefly, the rotarod was settled with a start speed of 5 rpm and the mice were placed on the rotating rod for 30 s. Then, the rotarod was accelerated to 40 rpm in 240 s. The time (s) when mice dropped from the rod was recorded. The results were
expressed as an average of two different trials and the interval time of each trial was 30 min.

Weights test. To test the forelimb strength of dystrophic mice treated or not with ACEA and rimonabant, four weights of 20, 33, 46, and 59 g were used. Mice were handled by the base of the tail and were allowed to grip the first weight (20 g) and a hold of 3 s was the criterion. If the mouse dropped the weight in less than 3 s, we tried the same weight again for a maximum of three times. If the mouse held it for 3 s, then we tried it on the next heaviest weight. The mouse was assigned the maximum time/weight achieved. The final total score is calculated as the product of the number of links in the heaviest chain held for the full 3 s, multiplied by the time (s) it is held.

Morphological analyses. For morphological analysis, gastrocnemius and quadriceps muscle were isolated from wild type, mdx mice injected with vehicle (DMSO) or rimonabant (SR141716, 0.5 mg kg\(^{-1}\) IP). After dissection, the muscles were rapidly embedded in Sakura Tissue-Tek oct (Gentaur) and frozen in isopentane-cooled liquid nitrogen for cryosection or fixed in PFA and embedded in paraffin. Tissue necrosis was identified by morphological alterations of myofibers (i.e., hypercontraction) or loss of sarcolemma integrity and by the presence of cellular debris in the surrounding interstitial space. Regenerated myofibers were identified by the presence of central nuclei, and the diameter or CSA of fibers was morphometrically analyzed using KS300 image analysis software (Carl Zeiss) or Image-Quant software (Leica).

Statistical analysis. We tested our datasets for normal distribution and chose an appropriate test accordingly using GraphPad Prism Version 7.0. Unpaired t-test was used to test two samples with equal variance. For more than two samples, we used one-way analysis of variance (ANOVA) followed by Bonferroni post hoc test. All error bars denote mean values ± SEM as indicated in every figure legend. The asterisk denote a * \(p < 0.05\) vs. the indicated experimental group.

Data availability

Additional raw data that support the findings of this study are available from the corresponding authors upon reasonable request. RNAseq data are available through SRA accession code SRP143532.

Received: 4 June 2017 Accepted: 22 August 2018

Published online: 27 September 2018

References

1. Falzarano, M. S., Scotton, C., Passarelli, C. & Ferlini, A. Duchenne muscular dystrophy: from diagnosis to therapy. Molecules 20, 18168–18184 (2015).
2. Nallamilli, B. R. R., Ankala, A. & Hegde, M. Molecular diagnosis of duchenne muscular dystrophy. Curr. Protoc. Hum. Genet., 9.25.1–9.25.29 (2014).
3. Magri, F. et al. Genotype and phenotype characterization in a large Duchenne muscular dystrophy – lost in polarity. Neuromuscul. Disord. 25, 1341–1378 (2015).
4. Chang, N. C., Chevalier, F. P. & Rudnicki, M. A. Satellite cells in muscular dystrophy: from basic mechanisms to gene therapy. Dis. Model. Mech. 8, 195–213 (2015).
5. Collins, C. A. & Morgan, J. E. Duchenne’s muscular dystrophy: animal models used to investigate pathogenesis and develop therapeutic strategies. Int. J. Exp. Pathol. 84, 165–172 (2003).
6. Cooper, B. J. Animal models of Duchenne and Becker muscular dystrophy. Br. Med. Bull. 51, 703–719 (1995).
7. McCreery, J. W., Hakim, C. H., McIntosh, M. A. & Duan, D. Animal models of Duchenne muscular dystrophy: from basic mechanisms to gene therapy. Dis. Model. Mech. 8, 195–213 (2015).
8. Seale, P. et al. PaX7 is required for the specification of myogenic satellite cells. Cell 102, 777–786 (2000).
9. Reimann, J. et al. PaX7 distribution in human skeletal muscle biopsies and myogenic tissue cultures. Cell Tissue Res. 315, 233–242 (2004).
10. McCreery, J. W., Hakim, C. H., McIntosh, M. A. & Duan, D. Animal models of Duchenne muscular dystrophy: from basic mechanisms to gene therapy. Dis. Model. Mech. 8, 195–213 (2015).
11. Bushby, K. et al. Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care. Lancet Neurol. 9, 177–189 (2010).
12. Ryberg, E. et al. Identification and characterisation of a novel splice variant of the human CB1 receptor. FEBS Lett. 579, 259–264 (2005).
13. Laprarie, R. B., Kelly, M. E. M. & Denovan-Wright, E. M. The dynamic nature of type 1 cannabinoid receptor (CB1(1)) gene transcription. Br. J. Pharmacol. 167, 1583–1592 (2012).
14. Choi, M.-C. et al. HDAC4 promotes PaX7-dependent satellite cell activation and muscle regeneration. EMBO Rep. 15, 1175–1183 (2014).
15. Iannotti, F. A. et al. Expression, localization, and pharmacological role of Kv7 potassium channels in skeletal muscle proliferation, differentiation, and survival after myotoxic insults. J. Pharmacol. Exp. Ther. 332, 811–820 (2010).
16. Syverud BG et al. Isolation and Purification of Satellite Cells for Skeletal Muscle Tissue Engineering. J. Regen Med. 3, 117 (2014).
17. Aartsma-Rus, A. & van Putten, M. Assessing functional performance in the mdx mouse model. J. Vis. Exp. https://doi.org/10.3791/51303 (2014).
18. Deacon, R. M. J. Measuring the strength of mice. J. Vis. Exp. https://doi.org/10.3791/2610 (2013).
19. Guardiola, O. et al. Cripto regulates skeletal muscle regeneration and modulates satellite cell differentiation by antagonizing myostatin. Proc. Natl Acad. Sci. USA 109, E3231–E3240 (2012).
20. Edgerton, V. R., Smith, J. L. & Simpson, D. R. Muscle fibre type populations of human leg muscles. Histochim. J. 7, 259–266 (1975).
21. Zhao, D. et al. Peripheral endocannabinoids regulate skeletal muscle development and maintenance. Eur. J. Transl. Myol. 20, 167 (2010).
22. Pischiatti, F. et al. Effect of dietary krill oil supplementation on the endocannabinoide of metabolically relevant tissues from high-fat-fed mice. Nutr. Metab. (Lond.) 8, 51 (2011).
23. Steinberg, S. F. Structural basis of protein kinase C isofrom function. Physiol. Rev. 88, 1341–1378 (2008).
24. Griner, E. M. & Kazanetz, M. G. Protein kinase C and other diacylglycerol effectors in cancer. Nat. Rev. Cancer 7, 281–294 (2007).
25. Delmas, P. & Brown, D. A. Pathways modulating neural KCNQ/MKV7 potassium channels. Nat. Rev. Neurosci. 6, 850–862 (2005).
26. Lozanoska-Ochsner, B. et al. Targeting early PKCβ-dependent T-cell infiltration of dystrophic muscle reduces disease severity in a mouse model of muscular dystrophy. J. Pathol. 244, 323–333 (2018).
27. Madaro, L. et al. PKCθ ablation alleviates functional decline and reduces muscle pathology in a mouse model of muscular dystrophy. Plos ONE 7, e31513 (2012).
28. Boldrin, L., Zammit, P. S. & Morgan, J. E. Satellite cells from dystrophic muscle retain regenerative capacity. Stem Cell Res. 14, 20–29 (2015).
29. Schuierer, M. M., Mann, C. J., Bilsboe, H., Huxley, C. & Hughes, S. M. Analyses of the differentiation potential of satellite cells from myoβ−/−, mdx, and PMP22 C22 mice. BMC Musculoskelet. Disord. 16, 5 (2015).
30. Maier, F. & Bornemann, A. Comparison of the muscle fiber diameter and satellite cell frequency in human muscle biopsies. Muscle Nerve 22, 578–583 (1999).
31. Morgan, J. E. & Zammit, P. S. Direct effects of the pathogenic mutation on satellite cell function in muscular dystrophy. Exp. Cell Res. 316, 3100–3108 (2010).
32. Rajesh, M. et al. Cannabinoid 1 receptor promotes cardiac dysfunction, oxidative stress, inflammation, and fibrosis in diabetic cardiomyopathy. Diabetes 61, 716–727 (2012).
45. Kaplan, B. L. F. The role of CB1 in immune modulation by cannabinoids. Pharmacol. Ther. 137, 365–374 (2013).
46. Costa, B. et al. Effect of the cannabinoid CB1 receptor antagonist, SR141716, on nociceptive response and nerve demyelination in rodents with chronic constriction injury of the sciatic nerve. Pain 116, 52–61 (2005).
47. Blake, D. J., Weir, A., Newey, S. E. & Davies, K. E. Function and genetics of dystrophin and dystrophin-related proteins in muscle. Physiol. Rev. 82, 291–329 (2002).
48. Monaco, A. P. Dystrophin, the protein product of the Duchenne/Becker muscular dystrophy gene. Trends Biochem. Sci. 14, 412–415 (1989).
49. Aartsma-Rus, A., Van Deutekom, J. C. T., Fokkema, I. F., Van Ommen, G.-J. B. & Den Dunnen, J. T. Entries in the Leiden Duchenne muscular dystrophy mutation database: an overview of mutation types and paradoxical cases that confirm the reading-frame rule. Muscle Nerve 34, 135–144 (2006).
50. Ferreiro, V. et al. Asymptomatic Becker muscular dystrophy in a family with a multixen deletion. Muscle Nerve 39, 239–243 (2009).
51. Matthews, E., Brassington, R., Kuntzer, T., Jichi, F. & Manzur, A. Y. Corticosteroids for the treatment of Duchenne muscular dystrophy. Cochrane Database Syst. Rev., CD003725, https://doi.org/10.1002/14651858.CD003725.pub4 (2016).
52. Trujillo, X., Sánchez-Pastor, E., Andrade, F. & Huerta, M. Presence and colocalization of type-1 cannabinoid receptors with acetylcholine receptors in the motor end-plate of twitch skeletal muscle fibers in the frog. J. Membr. Biol. 247, 1199–1205 (2014).
53. Sanchez-Pastor, E., Trujillo, X., Huerta, M. & Andrade, F. Effects of cannabinoids on synaptic transmission in the frog neuromuscular junction. J. Pharmacol. Exp. Ther. 321, 439–445 (2007).
54. Huerta, M. et al. Effects of cannabinoids on caffeine contractures in slow and fast skeletal muscle fibers of the frog. J. Membr. Biol. 229, 91–99 (2009).

Acknowledgements
The authors wish to thank Dr. Gennaro Andolfi, Enrico Mazzarella, Roberta Verde, Roberta Imperatore (Consiglio Nazionale delle Ricerche, Naples, IT) and Lorenzo Schiaffino (Department of Neuroscience Biomedicine and Movement, Section of Physiology and Psychology, University of Verona, 37134 Verona, IT) for technical assistance.

Author contributions
F.A.I. and V.D. designed the research and wrote the manuscript; F.A.I., S.A., E.M., E.P., F. P., O.G., V.S., S.C., G.B. and E.G. conducted the research; F.A.I., E.P., O.G., G.M., P.L.P., R.C., D.C. and V.D. analyzed the data.

Additional information
Supplementary Information accompanies this paper at https://doi.org/10.1038/s41467-018-06267-1.

Competing interests: The authors declare no competing interests.

Reprints and permission information is available online at http://npg.nature.com/reprintsandpermissions/